Abstract:In this work we disclose a new family of biscyclometallated Ir( III ) complexes of the general formula [Ir(C^N) 2 (N^N)]Cl ( IrL1–IrL5 ), where HC^N is 1-phenyl-β-carboline and N^N ligands ( L1–L5 ) are different diimine ligands that differ from each other in the number of aromatic rings fused to the bipyridine scaffold. The photophysical properties of IrL1–IrL5 were thoroughly studied, and theoretical calculations were performed for a deeper comprehension of the respective variations along the series. All complexes exhibited high photostability under blue light irradiation. An increase in the number of aromatic rings led to a reduction in the HOMO–LUMO band gap causing a red-shift in the absorbance bands. Although all the complexes generated singlet oxygen ( 1 O 2 ) in aerated aqueous solutions through a photocatalytic process, IrL5 was by far the most efficient photosensitizer. Consequently, IrL5 was highly active in the photocatalytic oxidation of NADH. The formation of aggregates in DMSO at a high concentration (25 mM) was confirmed using different techniques, but was proved to be negligible in the concentration range of biological experiments. Moreover, ICP-MS studies proved that the cellular uptake of IrL2 and IrL3 is much better relative to that of IrL1 , IrL4 and IrL5 . The antiproliferative activity of IrL1–IrL5 was investigated in the dark and under blue light irradiation against different cancer cell lines. Complexes IrL1–IrL4 were found to be cytotoxic under dark conditions, while IrL5 turned out to be weakly cytotoxic. Despite the low cellular uptake of IrL5 , this derivative exhibited a high increase of cytotoxicity upon blue light irradiation resulting in photocytotoxicity indexes (PI) up to 38. IrL1–IrL4 showed lower photocytotoxicity indexes ranging from 1.3 to 17.0. Haemolytic experiments corroborated the compatibility of our complexes with red blood cells. Confocal microscopy studies proved their accumulation in mitochondria, leading to mitochondrial membrane depolarization, and ruled out their localization in lysosomes. Overall, the mitochondria-targeted activity of IrL5 , which inhibits considerably the viability of cancer cells upon blue light irradiation, allows us to outline this PS as a new alternative to traditional chemotherapeutic agents.

Lysosome-targeted Cyclometalated Ir(III) Complexes as Photosensitizer/Photoredox Catalysis for Cancer Therapy

Cyclometalated Ir(III) Complexes as Lysosome-Targeted Photodynamic Anticancer Agents

Mitochondria-targeted cyclometalated iridium (III) complex for H2S-responsive intracellular redox regulation as potent photo-oxidation anticancer agent

Lysosome-localization and tumor-targeting of novel photosensitizers enhance the ablation of cancer

A Pair of Deep Red Phosphorescent Responsive Emissive Cyclometalated Iridium (III) Complexes as Carbonic Anhydrase Inhibitor and Effective Theranostic Photosensitizer

Cyclometalated iridium(iii) complex nanoparticles for mitochondria-targeted photodynamic therapy

Lysosomal Targeted Cyclometallic Iridium(III) Salicylaldehyde-Coumarin Schiff Base Complexes and Anticancer Application

Targeted photoredox catalysis in cancer cells

Self-Chemiluminescence-Triggered Ir(III) Complex Photosensitizer for Photodynamic Therapy against Hypoxic Tumor

Photostable Iridium(III) Cyclometallated Complex is an Efficient Photosensitizer for Killing Multiple Cancer Cell Lines and 3D Models under Low Doses of Visible Light

Towards efficient Ir(iii) anticancer photodynamic therapy agents by extending π-conjugation on N^N ligands

Microtubule polymerization induced by iridium‐fullerene photosensitizers for cancer immunotherapy via dual‐reactive oxygen species regulation strategy

Anticancer activity and mechanism studies of photoactivated iridium(III) complexes toward lung cancer A549 cells

High Photocytotoxicity Iridium(III) Complex Photosensitizer for Photodynamic Therapy Induces Antitumor Effect Through GPX4‐Dependent Ferroptosis

Rational design of iridium-porphyrin conjugates for novel synergistic photodynamic and photothermal therapy anticancer agents

Aggregation-induced emission-active iridium (III)-based mitochondria-targeting nanoparticle for two-photon imaging-guided photodynamic therapy

Cyclometalated Iridium(III) Complexes as High-Sensitivity Two-Photon Excited Mitochondria Dyes and Near-Infrared Photodynamic Therapy Agents

Synthetic Ease and Exceptional In Vivo Performance of Pyrazole-based Cyclometallated Iridium Complexes

Precise ligand engineering of Ir(III)-based photosensitizer with aggregation-induced emission for image-guided photodynamic therapy

Cyclometalated iridium(III) tetrazine complexes for mitochondria-targeted two-photon photodynamic therapy

Light Switchable Ir(III)-Based Photosensitizers: A Dual-State System for Non-Invasive, Reversible ROS Control in Tumor Therapy